 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The company’s R&amp;D expenditure will come down to 7-7.5 percent of sales after the disinvestment in Glenmark Lifesciences. It was virtually double, at 14.2 percent of sales, in FY 17-18

After API subsidiary sale, Glenmark aims to check R&amp;D spends, expand margins

According to a regulatory filing, Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma to divest 75 percent stake in Glenmark Life Sciences for Rs 5,651.5 crore, at a price of Rs 615 per share.

Glenmark Pharma shares falls 5% after subsidiary stake sale to Nirma

Saldhana added that the management of Glenmark Lifesciences will remain intact

Glenmark Life Sciences deal to reduce parent’s debt, make it net cash positive: CMD

With this acquisition, the Ahmedabad-headquartered Nirma group founded by Dr Karsanbhai Patel has forayed into the API segment. Glenmark Pharma, the parent of Glenmark Life Sciences will use the deal proceeds towards repayment of debt

Nirma makes big pharma push; acquires 75% in Glenmark Life Sciences for Rs 5,651 cr

CNBC Awaaz reported that parent Glenmark Pharmaceuticals was looking to reduce its stake in the company without sharing the details

Glenmark Life Sciences gains on parent Glenmark Pharma plan to pare stake

With the continuous nine-day winning streak, the support level continues to shift higher as we now see immediate support in the zone of 17,700 - 17,600; whereas 200-SMA around 17,500 is likely to act as a sacrosanct level

Top 10 trading ideas for next 3-4 weeks as bulls look charged up for third straight week

Glenmark Life Standalone December 2022 Net Sales at Rs 540.73 crore, up 3.49% Y-o-Y

Glenmark Life Standalone September 2022 Net Sales at Rs 509.30 crore, down 9.34% Y-o-Y

PCBL was up nearly 3 percent at Rs 136.35, the highest closing level since September 20 and formed decent bullish candlestick pattern on the daily charts with higher volumes in last 13 consecutive sessions. The stock has been in an uptrend since the double bottom kind of formation.

Trade Spotlight | What should you do with Bata India, PCBL, Glenmark Life Sciences on Wednesday?

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. Its products focuses on chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes. The company was founded on June 23, 2011 and is headquartered in Mumbai, India.

Watchers	60
52-Wk Low	370.00
52-Wk High	675.00

Market Cap	76.32B
Volume (M)	130,710.00
52-Wk High	675.00
52-Wk Low	370.00

GLS.NSE Glenmark Life Sciences Ltd.

About

Feed

News

Fundamentals